Non-interventional Study for the Determination of Molecular Resistance Profiling to Targeted Therapies in Patients With Neoplastic Disease

Fondazione del Piemonte per l'Oncologia15 sites in 1 country2,500 target enrollmentMarch 30, 2011

ConditionsSolid Tumors

Overview

Phase: N/A
Intervention: Not specified
Conditions: Solid Tumors
Sponsor: Fondazione del Piemonte per l'Oncologia
Enrollment: 2500
Locations: 15
Primary Endpoint: number of patient correctly sampled
Status: Active, Not Recruiting
Last Updated: last month

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The main purpose of this study is to define the molecular profile of selected solid tumors. From each participants will be collected biological materials for molecular analysis, including saliva, blood and vital tumor tissue derived form surgical or biopsy procedures. Whereas possible, vital tumor specimens will be inoculated and propagated in immunocompromised NOD/SCID mice to study the genetic correlations between genetic status and response to target drugs.

Registry

clinicaltrials.gov

Start Date

March 30, 2011

End Date

March 31, 2026

Last Updated

last month

Study Type

Observational

Sex

All

Investigators

Sponsor

Fondazione del Piemonte per l'Oncologia

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients with at least one of the following selected solid tumors:
•Colorectal Cancer (primary or with synchronous/metachronous liver metastases)
•Prostate Cancer
•Head \& Neck Tumors
•Gastric Cancer
•Glioblastoma
•Breast Cancer
•Hepatocarcinoma
•Biliary Tract Carcinoma
•Lung Cancer (primary)

Exclusion Criteria

Not provided

Outcomes

Primary Outcomes

number of patient correctly sampled

Time Frame: through study completion, an average of five years

number of patients with biological samples idoneous for molecular profiling testing (nucleic acid extraction, protein) over all recruited patients.

Secondary Outcomes

number of patients with detected genetic alterations that respond to treatments assigned by physician.(through study completion, an average of five years)